Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 199

Sort by

Sort Order Select

Journal Articles

Detection of Recurrent Mutations, Immunoglobulin Rearrangements and Copy Number Changes in Cell-Free DNA and Bone Marrow on Patients with Waldenstrom's Macroglobulinemia over a Course of Treatment

Signy Chow, Arnavaz Danesh, Kim Roos, Suzanne Trudel, Trevor J. Pugh, Christine I Chen, Neil Berinstein

Blood (2024) 144 (Supplement 1): 6215.

https://doi.org/10.1182/blood-2024-201658

Published: 2024

Journal Articles

Long Term Survivors (>15 years) of Multiple Myeloma: Patient Characteristics and Morbidity Burden

Rintu Sharma, Karla Alexandra Sanchez, Badraa Muharib, Esther Masih-Khan, Eshetu G. Atenafu, Harjot Vohra, Sita D. Bhella, Christine I Chen, Guido Lancman, Vishal Kukreti, Anca Prica, Donna E Reece, Rodger E Tiedemann, Suzanne Trudel, Chloe Yang, A. Keith Stewart

Blood (2024) 144 (Supplement 1): 7841.

https://doi.org/10.1182/blood-2024-208502

Published: 2024

Journal Articles

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Blood (2024) 144 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2024-199542

Published: 2024

Journal Articles

Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies

Rintu Sharma, Pamella Paul, Esther Masih-Khan, Eshetu G. Atenafu, Harjot Vohra, Sita D. Bhella, Christine I Chen, Vishal Kukreti, Guido Lancman, Donna E Reece, A. Keith Stewart, Rodger E Tiedemann, Chloe Yang, Suzanne Trudel

Blood (2024) 144 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2024-207919

Published: 2024

Journal Articles

Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study

Sahar Khan, Salman Basrai, Esther Masih-Khan, Harjot Vohra, Donna Reece, Suzanne Trudel, Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E Tiedemann, Anca Prica, Aaron Schimmer, Sagi Abelson, Christine I Chen

Blood (2024) 144 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2024-210717

Published: 2024

Journal Articles

Handgrip Strength - Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma

Steven Shih, Harjot Vohra, Anup Joseph Devasia, Sahar Khan, Eshetu Atenafu, Donna Reece, Suzanne Trudel, A. Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E. Tiedemann, Anca Prica, Eugene Leung, Christine I Chen

Blood (2024) 144 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2024-198797

Published: 2024

Journal Articles

First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2024-199174

Published: 2024

Journal Articles

Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide

Tracy T. Chow, Nicholas Stong, Saleh Tamim, Chad C. Bjorklund, Antonina Kurtova, Keyur Desai, Joseph T. Hadala, Cynthia Donahue, Phillip Koo, Yue Zhu, Jessica Katz, Anita K. Gandhi, Suzanne Trudel, Nizar J. Bahlis, Paul G. Richardson, Michael Amatangelo

Blood (2024) 144 (Supplement 1): 3261.

https://doi.org/10.1182/blood-2024-199019

Published: 2024

Journal Articles

Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)

David H. Vesole, Thomas G Martin, Suzanne Trudel, Henning Schade, Samantha Shenoy, Noa Biran, Jeffrey Lee Wolf, Jeffrey V Matous, Pamela Munster, Savannah Berkeley, Jesús G Berdeja

Blood (2024) 144 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2024-209597

Published: 2024

Journal Articles

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Blood (2024) 144 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2024-199282

Published: 2024

Journal Articles

Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin

Anup Joseph Devasia, Olsen Chan, Harjot Vohra, Esther Masih-Khan, Chloe Yang, Sita Bhella, Rodger E Tiedemann, Vishal Kukreti, Christine I Chen, Keith Stewart, Donna Reece, Suzanne Trudel, Guido Lancman

Blood (2024) 144 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2024-209131

Published: 2024

Journal Articles

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Donna E Reece, Giovanni Piza Rodriguez, Mariela A Pantoja, Eshetu G Atenafu, Darrell White, Irwindeep Sandhu, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger E Tiedemann, Christine I Chen

Blood (2024) 144 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2024-206247

Published: 2024

Journal Articles

Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma

Dor D. Abelman, Jenna Eagles, Aimee Wong, Saumil Shah, Stephanie Pedersen, Sarah Bridges, Cecilia Bonolo De Campos, Darrell White, Irwindeep Sandhu, Kevin Song, Zac McDonald, Abir Khaled, Liqiang Yang, Alli Murugesan, Anthony Reiman, Suzanne Trudel, Trevor J. Pugh

Blood (2024) 144 (Supplement 1): 3338.

https://doi.org/10.1182/blood-2024-208740

Published: 2024

Journal Articles

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Martha L Louzada, Donna E. Reece, Arleigh McCurdy, Rami Kotb, Ibraheem Othman, Hira Mian, Toni Lin, Michael P Chu, Darrell White, Stephen Parkin, Engin Gul, Aniba Khan, Suzanne Trudel

Blood (2023) 142 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2023-174993

Published: 2023

Journal Articles

Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Anup J Devasia, Sahar Khan, Eshetu Atenafu, Harjot Vohra, Frédéric Larose, Donna Reece, Suzanne Trudel, A. Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E. Tiedemann, Anca Prica, Monica Monchis, Eugene Leung, Christina Zeglinski, Zubaida Mohamed, Christine Chen

Blood (2023) 142 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2023-190310

Published: 2023

Journal Articles

Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Sahar Khan, Salman Basrai, Donna Reece, Sita D. Bhella, Vishal Kukreti, Anca Prica, A. Keith Stewart, Suzanne Trudel, Harjot Vohra, Chloe Yang, Sagi Abelson, Christine Chen

Blood (2023) 142 (Supplement 1): 760.

https://doi.org/10.1182/blood-2023-190978

Published: 2023

Journal Articles

Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Dor D. Abelman, Jenna Eagles, Stephanie Pedersen, Arnavaz Danesh, Danielle Croucher, Jeff P. Bruce, Stephenie D. Prokopec, Ellen N. Wei, Saumil Shah, Alli Murugesan, Anthony Reiman, Suzanne Trudel, Trevor J. Pugh

Blood (2023) 142 (Supplement 1): 4693.

https://doi.org/10.1182/blood-2023-173685

Published: 2023

Journal Articles

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2023-174550

Published: 2023

Journal Articles

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Nizar J Bahlis, Suzanne Trudel, Christopher Maisel, Lisa X. Lee, Jorge Monge, Claudia Paba Prada, Sarah M. Larson, Guenther Koehne, Yogesh Jethava, Wei Dong Ma, Cristina De Nicolo, Isabel Perez-Cruz

Blood (2023) 142 (Supplement 1): 6737.

https://doi.org/10.1182/blood-2023-189700

Published: 2023

Journal Articles

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Paul G. Richardson, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z. Orlowski, Kihyun Kim, María-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Alessia Spirli, Ignacio Casas-Avilés, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Nizar J. Bahlis

Blood (2022) 140 (Supplement 1): 1366–1368.

https://doi.org/10.1182/blood-2022-157945

Published: 2022

NARROW

Detection of Recurrent Mutations, Immunoglobulin Rearrangements and Copy Number Changes in Cell-Free DNA and Bone Marrow on Patients with Waldenstrom's Macroglobulinemia over a Course of Treatment

Long Term Survivors (>15 years) of Multiple Myeloma: Patient Characteristics and Morbidity Burden

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies

Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study

Handgrip Strength - Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma

First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)

Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide

Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only